<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Intravenous tissue plasminogen activator (t-PA) is a recent proven effective treatment for <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> patients </plain></SENT>
<SENT sid="1" pm="."><plain>However, the use of t-PA in some special settings is controversial </plain></SENT>
<SENT sid="2" pm="."><plain>One of these is the presence of a cardiac <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e>, given that the use of t-PA could potentially accelerate breakup of the <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> and cause additional embolisms </plain></SENT>
<SENT sid="3" pm="."><plain>The authors describe the case of a cardiological patient with a cardiac <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> who was given IV t-PA for <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> treatment without complications </plain></SENT>
<SENT sid="4" pm="."><plain>We discuss the necessity or not of a 24 hours delay before <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> administration in these special patients </plain></SENT>
</text></document>